Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP
Ofir Livne, Dvora Shmulewitz, Claire Walsh, Deborah S. Hasin
Addiction August 17, 2022 DOI: 10.1111/add.15987 via OpenAlex
Summary
AI-generated from the abstractHallucinogen use in the United States has shifted in opposite directions across age groups since 2002. Among adolescents aged 12–17, use declined, while adults aged 26 and older showed increased use, particularly after 2015. By 2019, over 5.5 million adults aged 18 and older were estimated to have used hallucinogens in the past year. Lysergic acid diethylamide (LSD) use rose across all age groups, while ecstasy use fell among adolescents and adults. Phencyclidine (PCP) use decreased overall and among younger age groups. These trends come from nationally representative survey data spanning 2002 to 2019.
Study at a glance
| Characteristics | Cross-sectional Peer reviewed |
|---|---|
| Sample size | 1,006,051 |
| Population | US general population aged 12 years and older |
| Topics | LSD MDMA Psilocybin |
| Keywords | Hallucinogen Medicine |
| Citations | 90 |
| Key finding | Hallucinogen use increased among adults aged 26 and older between 2015 and 2019, while decreasing among adolescents aged 12–17 since 2002. |
Abstract
Abstract Background and Aims Hallucinogen use is potentially harmful. Information on whether such use has increased in recent decades is lacking. This study assessed overall and age‐specific time trends in the prevalence of 12‐month hallucinogen use in the US general population. Design Cross‐sectional. Setting Data from the US National Survey on Drug Use and Health, 2002–19. Participants Respondents aged ≥ 12 years ( n = 1 006 051). Measurements Predictors were continuous years. Outcome variables included any hallucinogen use and use of lysergic acid diethylamide (LSD), ecstasy and phencyclidine (PCP) in the past year. Socio‐demographic variables (gender, age, race/ethnicity, educational level and family income) were covariates. Findings Overall, hallucinogen use increased between 2015 and 2019 [prevalence difference (PD) = +0.44, P < 0.05]. Since 2002, hallucinogen use has increased in adults aged ≥ 26 years (PD, 2002–14 = +0.24, P < 0.05; PD, 2015–19 = +0.45, P < 0.001) and decreased in adolescents aged 12–17 years (PD, 2002–14 = −1.60, P < 0.0001; PD, 2015–19 = −0.73, P < 0.001). Ecstasy use has decreased in adolescents (PD, 2002–14 = −0.56, P < 0.001), adults aged 18–25 years (PD, 2015–19 = −0.96, P < 0.01) and ≥ 26 years (PD, 2015–19 = −0.13, P < 0.05). LSD use between 2002 and 2019 increased overall (PD = +0.71, P < 0.0001) and in all age groups (12–17: PD = +0.67, P < 0.001; 18–25: PD = +3.12, P < 0.0001; ≥ 26: PD = +0.36, P < 0.0001). Conversely, PCP use between 2002 and 2019 decreased overall (PD = –0.06, P < 0.001), in adolescents (PD = –0.24, P < 0.001) and young adults (PD = –0.32, P < 0.0001). Conclusions Since 2002, hallucinogen use in the United States has decreased among adolescents but increased in adults and is now estimated to affect more than 3 million adults aged 26+ years and more than 5.5 million adults aged 18+ years.